Drugs / Feiba VH
Feiba VH
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00108797 | Sep 2001 → Feb 2006 | hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Feiba VH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00108797 ↗ |
| Known as | Factor Eight Inhibitor Bypassing Activity | “This study evaluated efficacy and safety of rFVIIa and an activated prothrombin complex concentrate (APCC; Factor Eight Inhibitor Bypassing Activity [FEIBA], Baxter AG, Vienna,...” PMID 18081834 ↗ Dec 2007 |
| Known as | FEIBA | “This study evaluated efficacy and safety of rFVIIa and an activated prothrombin complex concentrate (APCC; Factor Eight Inhibitor Bypassing Activity [FEIBA], Baxter AG, Vienna,...” PMID 18081834 ↗ Dec 2007 |
| Modality | Protein / enzyme biologic | “activated prothrombin complex concentrate (APCC; Factor Eight Inhibitor Bypassing Activity [FEIBA], Baxter AG, Vienna, Austria)” PMID 18081834 ↗ Dec 2007 |